Skip to main content
Erschienen in: Acta Neuropathologica 4/2017

18.08.2017 | Review

The 2017 World Health Organization classification of tumors of the pituitary gland: a summary

verfasst von: M. Beatriz S. Lopes

Erschienen in: Acta Neuropathologica | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The 4th edition of the World Health Organization (WHO) classification of endocrine tumors has been recently released. In this new edition, major changes are recommended in several areas of the classification of tumors of the anterior pituitary gland (adenophypophysis). The scope of the present manuscript is to summarize these recommended changes, emphasizing a few significant topics. These changes include the following: (1) a novel approach for classifying pituitary neuroendocrine tumors according to pituitary adenohypophyseal cell lineages; (2) changes to the histological grading of pituitary neuroendocrine tumors with the elimination of the term “atypical adenoma;” and (3) introduction of new entities like the pituitary blastoma and re-definition of old entities like the null-cell adenoma. This new classification is very practical and mostly based on immunohistochemistry for pituitary hormones, pituitary-specific transcription factors, and other immunohistochemical markers commonly used in pathology practice, not requiring routine ultrastructural analysis of the tumors. Evaluation of tumor proliferation potential, by mitotic count and Ki-67 labeling index, and tumor invasion is strongly recommended on individual case basis to identify clinically aggressive adenomas. In addition, the classification offers the treating clinical team information on tumor prognosis by identifying specific variants of adenomas associated with an elevated risk for recurrence. Changes in the classification of non-neuroendocrine tumors are also proposed, in particular those tumors arising in the posterior pituitary including pituicytoma, granular cell tumor of the posterior pituitary, and spindle cell oncocytoma. These changes endorse those previously published in the 2016 WHO classification of CNS tumors. Other tumors arising in the sellar region are also reviewed in detail including craniopharyngiomas, mesenchymal and stromal tumors, germ cell tumors, and hematopoietic tumors. It is hoped that the 2017 WHO classification of pituitary tumors will establish more biologically and clinically uniform groups of tumors, make it possible for practicing pathologists to better diagnose these tumors, and contribute to our understanding of clinical outcomes for patients harboring pituitary tumors.
Literatur
1.
Zurück zum Zitat Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP (1993) Cell type-specific expression of the pituitary transcription activator PIT-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 77:1275–1280PubMed Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP (1993) Cell type-specific expression of the pituitary transcription activator PIT-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 77:1275–1280PubMed
2.
Zurück zum Zitat Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S (1996) The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 81:2165–2170PubMed Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S (1996) The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 81:2165–2170PubMed
3.
Zurück zum Zitat Balogun JA, Monsalves E, Juraschka K, Parvez K, Kucharczyk W, Mete O et al (2015) Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr Pathol 26:63–70CrossRefPubMed Balogun JA, Monsalves E, Juraschka K, Parvez K, Kucharczyk W, Mete O et al (2015) Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr Pathol 26:63–70CrossRefPubMed
4.
Zurück zum Zitat Brat DJ, Wesseling P, Fuller GN, Roncaroli F (2016) Pituicytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenne C (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC Press, Lyon, pp 332–333 Brat DJ, Wesseling P, Fuller GN, Roncaroli F (2016) Pituicytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenne C (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC Press, Lyon, pp 332–333
5.
Zurück zum Zitat Coons SW, Estrada SI, Gamez R, White WL (2005) Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol 16:201–210CrossRefPubMed Coons SW, Estrada SI, Gamez R, White WL (2005) Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol 16:201–210CrossRefPubMed
6.
Zurück zum Zitat Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2105) Aggressive pituitary tumors. Neuroendocrinology 101:87–104CrossRef Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2105) Aggressive pituitary tumors. Neuroendocrinology 101:87–104CrossRef
7.
Zurück zum Zitat Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F et al (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101:143–150CrossRefPubMed Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F et al (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101:143–150CrossRefPubMed
9.
Zurück zum Zitat Covington MF, Chin SS, Osborn AG (2011) Pituicytoma, spindle cell oncocytoma, and granular cell tumor: clarification and meta-analysis of the world literature since 1893. AJNR Am J Neuroradiol 32:2067–2072CrossRefPubMed Covington MF, Chin SS, Osborn AG (2011) Pituicytoma, spindle cell oncocytoma, and granular cell tumor: clarification and meta-analysis of the world literature since 1893. AJNR Am J Neuroradiol 32:2067–2072CrossRefPubMed
10.
Zurück zum Zitat de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Bouron-Dal Soglio D et al (2014) Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol 128:111–122CrossRefPubMedPubMedCentral de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Bouron-Dal Soglio D et al (2014) Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol 128:111–122CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat De Caro MDB, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM et al (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40:105–114CrossRef De Caro MDB, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM et al (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40:105–114CrossRef
12.
Zurück zum Zitat Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed
13.
Zurück zum Zitat Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147:751–757CrossRef Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147:751–757CrossRef
14.
Zurück zum Zitat Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G et al (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172:791–801CrossRefPubMed Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G et al (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172:791–801CrossRefPubMed
15.
Zurück zum Zitat Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas—diagnosis and emerging treatments. Nat Rev Endocrinol 10:423–435CrossRefPubMed Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas—diagnosis and emerging treatments. Nat Rev Endocrinol 10:423–435CrossRefPubMed
16.
Zurück zum Zitat Dupuy M, Bonneville F, Grunenwald S, Breibach F, Delisle MB, Chaynes P et al (2012) Primary sellar neuroblastoma. A new case and review of literature. Ann Endocrinol (Paris) 73:216–221CrossRef Dupuy M, Bonneville F, Grunenwald S, Breibach F, Delisle MB, Chaynes P et al (2012) Primary sellar neuroblastoma. A new case and review of literature. Ann Endocrinol (Paris) 73:216–221CrossRef
17.
Zurück zum Zitat Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV et al (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo clinic experience. Clin Endocrinol (Oxf) 71:92–99CrossRef Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV et al (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo clinic experience. Clin Endocrinol (Oxf) 71:92–99CrossRef
18.
Zurück zum Zitat Friend KE, Chiou YK, Laws ER Jr, Lopes MB, Shupnik MA (1993) PIT-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas. J Clin Endocrinol Metab 77:1281–1286PubMed Friend KE, Chiou YK, Laws ER Jr, Lopes MB, Shupnik MA (1993) PIT-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas. J Clin Endocrinol Metab 77:1281–1286PubMed
19.
Zurück zum Zitat Friend KE, Chiou YK, Lopes MB, Laws ER Jr, Hughes KM et al (1994) Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 78:1497–1504PubMed Friend KE, Chiou YK, Lopes MB, Laws ER Jr, Hughes KM et al (1994) Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 78:1497–1504PubMed
20.
Zurück zum Zitat Fuller GN, Brat DJ, Wesseling P, Roncaroli F (2016) Granular cell tumour of the sellar region. In: Louis DN, Ohgaki H, Wiestler OD, Cavenne C (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC Press, Lyon, pp 329–331 Fuller GN, Brat DJ, Wesseling P, Roncaroli F (2016) Granular cell tumour of the sellar region. In: Louis DN, Ohgaki H, Wiestler OD, Cavenne C (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC Press, Lyon, pp 329–331
21.
Zurück zum Zitat George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV et al (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330–1336CrossRefPubMed George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV et al (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330–1336CrossRefPubMed
22.
Zurück zum Zitat Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary—immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29:511–524CrossRefPubMed Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary—immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29:511–524CrossRefPubMed
24.
Zurück zum Zitat Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S et al (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17CrossRefPubMed Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S et al (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17CrossRefPubMed
25.
Zurück zum Zitat Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59:221–228CrossRefPubMed Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59:221–228CrossRefPubMed
26.
Zurück zum Zitat Kontogeorgos G, Kovacs K, Horvath E, Scheithauer BW (1991) Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications. J Neurosurg 74:243–247CrossRefPubMed Kontogeorgos G, Kovacs K, Horvath E, Scheithauer BW (1991) Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications. J Neurosurg 74:243–247CrossRefPubMed
27.
Zurück zum Zitat Kontogeorgos G, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV, Smyth HS et al (1992) Double adenomas of the pituitary: a clinicopathological study of 11 tumors. Neurosurgery 31:840–849CrossRefPubMed Kontogeorgos G, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV, Smyth HS et al (1992) Double adenomas of the pituitary: a clinicopathological study of 11 tumors. Neurosurgery 31:840–849CrossRefPubMed
28.
Zurück zum Zitat Kontogeorgos G, Thodou E (2016) The gonadotroph origin of null cell adenomas. Hormones (Athens) 15:243–247 Kontogeorgos G, Thodou E (2016) The gonadotroph origin of null cell adenomas. Hormones (Athens) 15:243–247
29.
Zurück zum Zitat Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072–4077CrossRefPubMed Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072–4077CrossRefPubMed
30.
Zurück zum Zitat Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692–696CrossRefPubMed Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692–696CrossRefPubMed
31.
Zurück zum Zitat Lania A, Mantovani G, Spada A (2003) Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med 228:1004–1017CrossRef Lania A, Mantovani G, Spada A (2003) Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med 228:1004–1017CrossRef
32.
Zurück zum Zitat Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18:326–334CrossRefPubMed Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18:326–334CrossRefPubMed
33.
Zurück zum Zitat Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK (2009) Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol 68:482–488CrossRefPubMed Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK (2009) Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol 68:482–488CrossRefPubMed
34.
Zurück zum Zitat Lloyd RV, Osamura RY (1997) Transcription factors in normal and neoplastic pituitary tissues. Microsc Res Tech 39:168–181CrossRefPubMed Lloyd RV, Osamura RY (1997) Transcription factors in normal and neoplastic pituitary tissues. Microsc Res Tech 39:168–181CrossRefPubMed
35.
Zurück zum Zitat Lloyd RV, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J et al (2004) Pituitary tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World health organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. IARC Press, Lyon, pp 10–13 Lloyd RV, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J et al (2004) Pituitary tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World health organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. IARC Press, Lyon, pp 10–13
36.
Zurück zum Zitat Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon
37.
Zurück zum Zitat Lopes MB, Salmon I, Nagy N, Decaestecker C, Pasteels JL, Laws ER Jr et al (1997) Computer-assisted microscope analysis of Feulgen-stained nuclei in gonadotroph adenomas and null-cell adenomas of the pituitary gland. Endocr Pathol 8:109–120CrossRefPubMed Lopes MB, Salmon I, Nagy N, Decaestecker C, Pasteels JL, Laws ER Jr et al (1997) Computer-assisted microscope analysis of Feulgen-stained nuclei in gonadotroph adenomas and null-cell adenomas of the pituitary gland. Endocr Pathol 8:109–120CrossRefPubMed
38.
Zurück zum Zitat Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115–121CrossRefPubMed Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115–121CrossRefPubMed
39.
Zurück zum Zitat Lopes MBS, Fuller GN, Roncaroli F, Wesseling P (2016) Spindle cell oncocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenne C (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC Press, Lyon, pp 334–336 Lopes MBS, Fuller GN, Roncaroli F, Wesseling P (2016) Spindle cell oncocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenne C (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC Press, Lyon, pp 334–336
40.
Zurück zum Zitat Lopes MB, Sloan E, Polder J (2017) Mixed gangliocytoma-pituitary adenoma: insights on the pathogenesis of a rare sellar tumor. Am J Surg Pathol 41:586–595CrossRefPubMed Lopes MB, Sloan E, Polder J (2017) Mixed gangliocytoma-pituitary adenoma: insights on the pathogenesis of a rare sellar tumor. Am J Surg Pathol 41:586–595CrossRefPubMed
41.
Zurück zum Zitat Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF et al (2015) Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res 25:306–317CrossRefPubMedPubMedCentral Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF et al (2015) Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res 25:306–317CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Mahler C, Verhelst J, Klaes R, Trouillas J (1991) Cushing’s disease and hyperprolactinemia due to a mixed ACTH—and prolactin-secreting pituitary macroadenoma. Pathol Res Pract 187:598–602CrossRefPubMed Mahler C, Verhelst J, Klaes R, Trouillas J (1991) Cushing’s disease and hyperprolactinemia due to a mixed ACTH—and prolactin-secreting pituitary macroadenoma. Pathol Res Pract 187:598–602CrossRefPubMed
43.
Zurück zum Zitat Marques P, Korbonits M (2017) Genetic aspects of pituitary adenomas. Endocrinol Metab Clin North Am 46:335–374CrossRefPubMed Marques P, Korbonits M (2017) Genetic aspects of pituitary adenomas. Endocrinol Metab Clin North Am 46:335–374CrossRefPubMed
44.
Zurück zum Zitat McDonald WC, Banerji N, McDonald KN, Ho B, Macias V, Kajdacsy-Balla A (2017) Steroidogenic factor 1, PIT-1, and adrenocorticotropic hormone: a rational starting place for the immunohistochemical characterization of pituitary adenoma. Arch Pathol Lab Med 141:104–112CrossRefPubMed McDonald WC, Banerji N, McDonald KN, Ho B, Macias V, Kajdacsy-Balla A (2017) Steroidogenic factor 1, PIT-1, and adrenocorticotropic hormone: a rational starting place for the immunohistochemical characterization of pituitary adenoma. Arch Pathol Lab Med 141:104–112CrossRefPubMed
45.
Zurück zum Zitat Meij BP, Lopes MB, Vance ML, Thorner MO, Laws ER (2000) Double pituitary lesions in three patients with Cushing’s disease. Pituitary 3:159–168CrossRefPubMed Meij BP, Lopes MB, Vance ML, Thorner MO, Laws ER (2000) Double pituitary lesions in three patients with Cushing’s disease. Pituitary 3:159–168CrossRefPubMed
46.
Zurück zum Zitat Mete O, Lopes MB, Asa SL (2013) Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 37:1649–1694CrossRef Mete O, Lopes MB, Asa SL (2013) Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 37:1649–1694CrossRef
47.
Zurück zum Zitat Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F et al (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal PIT-1 lineage adenomas. Mod Pathol 29:131–142CrossRefPubMed Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F et al (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal PIT-1 lineage adenomas. Mod Pathol 29:131–142CrossRefPubMed
48.
Zurück zum Zitat Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A et al (2015) Histological criteria for atypical pituitary adenomas—data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3:50. doi:10.1186/s40478-015-0229-8 (Erratum. In: Acta Neuropathol Commun. 2016;4(1):21) CrossRefPubMedPubMedCentral Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A et al (2015) Histological criteria for atypical pituitary adenomas—data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3:50. doi:10.​1186/​s40478-015-0229-8 (Erratum. In: Acta Neuropathol Commun. 2016;4(1):21) CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A et al (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26:349–355CrossRefPubMed Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A et al (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26:349–355CrossRefPubMed
50.
Zurück zum Zitat Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82–91CrossRefPubMed Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82–91CrossRefPubMed
51.
Zurück zum Zitat Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Introduction. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon, p 13 Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Introduction. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon, p 13
52.
Zurück zum Zitat O’Toole SM, Dénes J, Robledo M, Stratakis CA, Korbonits M (2015) 15 years of paraganglioma: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer 22:T105–T122CrossRefPubMed O’Toole SM, Dénes J, Robledo M, Stratakis CA, Korbonits M (2015) 15 years of paraganglioma: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer 22:T105–T122CrossRefPubMed
53.
Zurück zum Zitat Peng P, Chen F, Zhou D, Liu H, Li J (2015) Neurocytoma of the pituitary gland: a case report and literature review. Biomed Rep 3:301–303PubMedPubMedCentral Peng P, Chen F, Zhou D, Liu H, Li J (2015) Neurocytoma of the pituitary gland: a case report and literature review. Biomed Rep 3:301–303PubMedPubMedCentral
54.
Zurück zum Zitat Perez-Rivas LG, Theodoropoulou M, Ferraù F, Nusser C, Kawaguchi K, Stratakis CA et al (2015) The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing’s disease. J Clin Endocrinol Metab 100:E997–E1004CrossRefPubMedPubMedCentral Perez-Rivas LG, Theodoropoulou M, Ferraù F, Nusser C, Kawaguchi K, Stratakis CA et al (2015) The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing’s disease. J Clin Endocrinol Metab 100:E997–E1004CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Preda V, Korbonits M, Cudlip S, Karavitaki N, Grossman AB (2014) Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Eur J Endocrinol 171:659–666CrossRefPubMed Preda V, Korbonits M, Cudlip S, Karavitaki N, Grossman AB (2014) Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Eur J Endocrinol 171:659–666CrossRefPubMed
56.
Zurück zum Zitat Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16:E7 (PMID: 15191336) CrossRefPubMed Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16:E7 (PMID: 15191336) CrossRefPubMed
57.
Zurück zum Zitat Ramírez C, Cheng S, Vargas G, Asa SL, Ezzat S, González B et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751CrossRefPubMed Ramírez C, Cheng S, Vargas G, Asa SL, Ezzat S, González B et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751CrossRefPubMed
58.
Zurück zum Zitat Ratliff JK, Oldfield EH (2000) Multiple pituitary adenomas in Cushing’s disease. J Neurosurg 93:753–761CrossRefPubMed Ratliff JK, Oldfield EH (2000) Multiple pituitary adenomas in Cushing’s disease. J Neurosurg 93:753–761CrossRefPubMed
59.
Zurück zum Zitat Rasul FT, Jaunmuktane Z, Khan AA, Phadke R, Powell M (2014) Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature. Acta Neurochir (Wien) 156:141–146CrossRef Rasul FT, Jaunmuktane Z, Khan AA, Phadke R, Powell M (2014) Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature. Acta Neurochir (Wien) 156:141–146CrossRef
60.
Zurück zum Zitat Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H et al (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76:769–775CrossRef Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H et al (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76:769–775CrossRef
61.
Zurück zum Zitat Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47:31–38CrossRefPubMed Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47:31–38CrossRefPubMed
62.
Zurück zum Zitat Rotondo F, Cusimano M, Scheithauer BW, Coire C, Horvath E, Kovacs K (2012) Atypical, invasive, recurring Crooke cell adenoma of the pituitary. Hormones (Athens) 11:94–100 Rotondo F, Cusimano M, Scheithauer BW, Coire C, Horvath E, Kovacs K (2012) Atypical, invasive, recurring Crooke cell adenoma of the pituitary. Hormones (Athens) 11:94–100
63.
Zurück zum Zitat Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 156:203–216CrossRefPubMed Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 156:203–216CrossRefPubMed
64.
Zurück zum Zitat Sahakitrungruang T, Srichomthong C, Pornkunwilai S, Amornfa J, Shuangshoti S, Kulawonganunchai S et al (2014) Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing’s disease. J Clin Endocrinol Metab 99:E1487–E1492CrossRefPubMed Sahakitrungruang T, Srichomthong C, Pornkunwilai S, Amornfa J, Shuangshoti S, Kulawonganunchai S et al (2014) Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing’s disease. J Clin Endocrinol Metab 99:E1487–E1492CrossRefPubMed
65.
Zurück zum Zitat Sanno N, Teramoto A, Sugiyama M, Itoh Y, Osamura RY (1996) Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. Am J Clin Pathol 106:16–21CrossRefPubMed Sanno N, Teramoto A, Sugiyama M, Itoh Y, Osamura RY (1996) Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. Am J Clin Pathol 106:16–21CrossRefPubMed
66.
Zurück zum Zitat Sano T, Kovacs K, Asa SL, Smyth HS (1990) Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary. Immunohistochemical and tissue culture studies of two cases. Virchows Arch A Pathol Anat Histopathol 417:361–367CrossRefPubMed Sano T, Kovacs K, Asa SL, Smyth HS (1990) Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary. Immunohistochemical and tissue culture studies of two cases. Virchows Arch A Pathol Anat Histopathol 417:361–367CrossRefPubMed
67.
Zurück zum Zitat Sano T, Yamada S, Jr Watson RE, Lindell EP, Ezzat S, Asa AL (2004) Null cell adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World health organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. IARC Press, Lyon, pp 33–34 Sano T, Yamada S, Jr Watson RE, Lindell EP, Ezzat S, Asa AL (2004) Null cell adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World health organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. IARC Press, Lyon, pp 33–34
68.
Zurück zum Zitat Scheithauer BW, Kovacs K, Horvath E, Kim DS, Osamura RY, Ketterling RP et al (2008) Pituitary blastoma. Acta Neuropathol 116:657–666CrossRefPubMed Scheithauer BW, Kovacs K, Horvath E, Kim DS, Osamura RY, Ketterling RP et al (2008) Pituitary blastoma. Acta Neuropathol 116:657–666CrossRefPubMed
69.
Zurück zum Zitat Scheithauer BW, Horvath E, Abel TW, Robital Y, Park SH, Osamura RY et al (2012) Pituitary blastoma: a unique embryonal tumor. Pituitary 15:365–373CrossRefPubMed Scheithauer BW, Horvath E, Abel TW, Robital Y, Park SH, Osamura RY et al (2012) Pituitary blastoma: a unique embryonal tumor. Pituitary 15:365–373CrossRefPubMed
70.
Zurück zum Zitat Scully KM, Rosenfeld MG (2002) Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231–2235CrossRefPubMed Scully KM, Rosenfeld MG (2002) Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231–2235CrossRefPubMed
71.
Zurück zum Zitat Tischler AS, Pacak K, Eisenhofer G (2014) The adrenal medulla and extra-adrenal paraganglia: then and now. Endocr Pathol 25:49–58CrossRefPubMed Tischler AS, Pacak K, Eisenhofer G (2014) The adrenal medulla and extra-adrenal paraganglia: then and now. Endocr Pathol 25:49–58CrossRefPubMed
72.
Zurück zum Zitat Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123–135CrossRefPubMed Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123–135CrossRefPubMed
73.
Zurück zum Zitat Umeoka K, Sanno N, Osamura RY, Teramoto A (2002) Expression of GATA-2 in human pituitary adenomas. Mod Pathol 15:11–17CrossRefPubMed Umeoka K, Sanno N, Osamura RY, Teramoto A (2002) Expression of GATA-2 in human pituitary adenomas. Mod Pathol 15:11–17CrossRefPubMed
74.
Zurück zum Zitat Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr (2003) Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53:1076–1084CrossRefPubMed Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr (2003) Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53:1076–1084CrossRefPubMed
75.
Zurück zum Zitat Xekouki P, Stratakis CA (2012) Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer 19:C33–C40CrossRefPubMedPubMedCentral Xekouki P, Stratakis CA (2012) Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer 19:C33–C40CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat Xu Z, Ellis S, Lee CC, Starke RM, Schlesinger D, Vance ML, Lopes MB, Sheehan J (2014) Silent corticotroph adenomas after stereotactic radiosurgery: a case–control study. Int J Radiat Oncol Biol Phys 90:903–910CrossRefPubMed Xu Z, Ellis S, Lee CC, Starke RM, Schlesinger D, Vance ML, Lopes MB, Sheehan J (2014) Silent corticotroph adenomas after stereotactic radiosurgery: a case–control study. Int J Radiat Oncol Biol Phys 90:903–910CrossRefPubMed
77.
Zurück zum Zitat Yamada S, Sano T, Takahashi M, Shishiba Y, Teramoto A (1995) Immunohistochemical heterogeneity within clinically nonfunctioning pituitary adenomas. Endocr Pathol 6:217–221CrossRefPubMed Yamada S, Sano T, Takahashi M, Shishiba Y, Teramoto A (1995) Immunohistochemical heterogeneity within clinically nonfunctioning pituitary adenomas. Endocr Pathol 6:217–221CrossRefPubMed
78.
Zurück zum Zitat Yildirim AE, Divanlioglu D, Nacar OA, Dursun E, Sahinoglu M, Unal T, Belen AD (2013) Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas. Turk Neurosurg 23:226–231PubMed Yildirim AE, Divanlioglu D, Nacar OA, Dursun E, Sahinoglu M, Unal T, Belen AD (2013) Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas. Turk Neurosurg 23:226–231PubMed
79.
Zurück zum Zitat Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344CrossRefPubMed Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344CrossRefPubMed
80.
Zurück zum Zitat Zafar M, Ezzat S, Ramyar L, Pan N, Smyth HS, Asa SL (1995) Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 80:3621–3627PubMed Zafar M, Ezzat S, Ramyar L, Pan N, Smyth HS, Asa SL (1995) Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 80:3621–3627PubMed
81.
Zurück zum Zitat Zaidi HA, Cote DJ, Dunn IF, Laws ER Jr (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 34:246–251CrossRefPubMed Zaidi HA, Cote DJ, Dunn IF, Laws ER Jr (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 34:246–251CrossRefPubMed
82.
Zurück zum Zitat Zieliński G, Maksymowicz M, Podgórski J, Olszewski WT (2013) Double, synchronous pituitary adenomas causing acromegaly and Cushing’s disease. A case report and review of literature. Endocr Pathol 24:92–99CrossRefPubMedPubMedCentral Zieliński G, Maksymowicz M, Podgórski J, Olszewski WT (2013) Double, synchronous pituitary adenomas causing acromegaly and Cushing’s disease. A case report and review of literature. Endocr Pathol 24:92–99CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat Zhu X, Rosenfeld MG (2004) Transcriptional control of precursor proliferation in the early phases of pituitary development. Curr Opin Genet Dev 14:567–574CrossRefPubMed Zhu X, Rosenfeld MG (2004) Transcriptional control of precursor proliferation in the early phases of pituitary development. Curr Opin Genet Dev 14:567–574CrossRefPubMed
Metadaten
Titel
The 2017 World Health Organization classification of tumors of the pituitary gland: a summary
verfasst von
M. Beatriz S. Lopes
Publikationsdatum
18.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Acta Neuropathologica / Ausgabe 4/2017
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-017-1769-8

Weitere Artikel der Ausgabe 4/2017

Acta Neuropathologica 4/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.